Today, LumiraDx stock in the pre-market continues to grow 42.35% and costs $11.84. During its last trading session, the company’s stock rose by 6.71% and traded at $8.43. LumiraDx (LMDX) announced today that the Central Medicines Control Organization of India has granted its emergency use authorization to conduct a SARS-CoV-2 antigen test for use in India.
The test detects the antigen nucleocapsid protein in a nasal swab in less than 12 minutes after the sample is applied. The LumiraDx SARS-CoV-2 antigen test demonstrated 97.6% positive consent and 96.6% negative consent with a PCR test for patients during the first twelve days of symptoms in clinical studies, making it one of the fastest and most sensitive antigen tests currently available on the market. After receiving an Emergency Use Authorization (EUA) from FDA in August 2020 and a CE Mark in September 2020, the test was made available in the US and Europe.